馃攳
6 Top Biotech Stocks To Buy Right Now - May 2022 - 1000% upside $OCGN $ATNF $CTXR $KMPH $NWBO Stock - YouTube
Channel: Paul Thomas Investing
[0]
let's talk about biotech what's up
[2]
investors and welcome back to the
[3]
channel today i want to talk about six
[5]
biotech companies that have huge upside
[7]
potential yes in this short video i will
[9]
cover six of the best biotech stocks on
[12]
the market right now each of these is
[14]
backed up by huge analysts price targets
[15]
of up to 10x i will look at the latest
[18]
developments for each company and the
[20]
upcoming catalyst that will drive these
[22]
stock prices in 2022. some of these
[24]
companies have expected catalyst as soon
[26]
as next week so stay to the end of the
[28]
video and don't miss out the big
[30]
question is are these good stocks to buy
[32]
right now
[33]
before we get into the video if you like
[35]
this content can i ask you to smash the
[37]
like button i'm aiming to get 300 likes
[39]
on this video help me achieve this goal
[42]
it literally costs you nothing but it
[43]
helps me out so much subscribe to the
[46]
channel if you're new and hit the bell
[47]
notification so you never miss out on a
[48]
video that has the potential to make you
[50]
money
[51]
i want to point out that i'm not a
[52]
financial advisor and this is not
[54]
financial advice now let's get into it
[56]
with the first stock on the list sidious
[58]
pharmaceuticals nasdaq ticker
[61]
ct xor
[62]
sidious is a late stage
[64]
biopharmaceutical company focused on the
[66]
development and commercialization of
[67]
critical care products with a pipeline
[70]
of anti-infectives
[72]
in cancer care oncology stem cell
[74]
therapy and unique prescription products
[77]
the company is developing five
[79]
proprietary products comprising of
[81]
ion attack
[83]
for the treatment of patients with
[84]
persistent or recurrent
[86]
cutaneous t cell lymphoma
[89]
minoloc an antibiotic lock solution to
[92]
treat patients with
[93]
catheter related bloodstream infections
[96]
halolido a cordial steroid to provide
[99]
anti-inflammatory and aesthetic relief
[101]
from hemorrhoids
[103]
minor wrap a gel based wrap for
[105]
reduction of tissue expander infections
[106]
following breast reconstructive
[108]
surgeries
[110]
and the company is also working on a
[111]
novel
[112]
stem cell therapy for the treatment of
[114]
acute inflammatory respiratory disorders
[117]
including acute respiratory
[119]
distress syndrome or herds
[122]
for which there is currently no
[123]
fda approved treatments
[125]
sidious has a series of upcoming
[127]
catalysts for 2022 as we can see here
[130]
sidious anticipates filing a bla for
[132]
iontech with the fda in the second half
[135]
of 2022 and has shown encouraging
[137]
top-line data from a phase 3 study
[140]
there is also upcoming trials for halo
[142]
lido and minolok too but is sidious
[144]
pharmaceuticals a good investment
[147]
analysts consider cities pharmaceuticals
[149]
to be a strong boy
[151]
three wall street analysts offering 12
[152]
month price targets with an average
[154]
price target of 667.
[157]
with a high forecast of 10 and a low
[159]
cost
[160]
and a low forecast of four this offers
[162]
significant upside from the current
[164]
price of just 103.
[166]
guys if you would like me to do a full
[168]
video on sidious pharmaceuticals
[171]
ticker ctxr
[173]
then comment this down below
[176]
next up is northwest biotherapeutics
[179]
this is an otc stock trading on the
[181]
otcqb ticker
[183]
in wbo
[185]
northwest biotherapeutics
[188]
is a clinical stage biotech company
[190]
focused on the development of
[191]
personalized cancer vaccines designed to
[194]
treat a broad range of solid tumor
[196]
cancers using a treatment to avoid the
[198]
side effects of chemotherapy drugs
[201]
northwest has a broad platform
[203]
technology dc vacs cell-based vaccines
[206]
the company's lead program is a 331
[209]
patient phase 3 trial of dc vax l for
[213]
newly diagnosed gbm which is the most
[216]
aggressive and lethal form of brain
[218]
cancer but the company has also
[220]
developed dc vax direct or inoperable
[223]
solid tumor cancers back in february
[226]
northwest began production of its first
[228]
dendritic cell
[230]
cancer vaccine for a compassionate use
[232]
patient at its production facility in
[234]
the uk the company anticipates that
[237]
phase 1a of the uk facility will have
[239]
the capacity to produce cancer vaccines
[241]
for between 450 and 500 patients per
[244]
year
[245]
and then just this week northwest
[247]
announced an upcoming presentation will
[249]
be made on may 10th by dr linda lao at
[252]
the frontiers of cancer immunotherapy
[254]
conference of the new york academy of
[256]
sciences but is northwest
[259]
biotherapeutics a good stock to buy
[261]
right now
[262]
because this company trades on the otc
[264]
there is no reliable analyst price
[266]
targets but this is beginning to gather
[268]
a lot of investor interest over the past
[271]
five weeks this stock has been on an
[272]
incredible run from just 70 cents on the
[275]
5th of april
[276]
up to its current price of 186. if you
[279]
want to hear more about this stock then
[280]
comment northwest down below
[283]
him firm
[285]
this is the nasdaq listed company with
[286]
the ticker kmph him farm is a speciality
[290]
pharmaceutical company focused on the
[292]
discovery and development of proprietary
[294]
pro drugs to treat serious medical
[297]
conditions through its proprietary lat
[299]
technology
[300]
they use this technology to generate
[302]
improved pro-drug versions of
[304]
fda-approved drugs as well as to
[306]
generate pro-drug versions of existing
[308]
compounds that may have applications for
[310]
new disease indications
[312]
kin firm's project product pipeline is
[315]
focused on the high need areas of adhd
[318]
and stimulant use disorder
[320]
in their pipeline kim farm currently
[322]
have two approved product products
[324]
and its product candidates are focused
[326]
around kp 1077 and kp 879 which are
[331]
being developed to treat sleep disorders
[333]
and stimulant use disorder
[335]
last month chem pump started their early
[338]
stage cardiovascular safety study data
[341]
from the study is expected in the third
[342]
quarter of 2022 and the company is
[344]
planning to initiate two mid-stage
[346]
studies in 2022 to evaluate
[349]
ap107 as treatment for hyperinsomnia and
[352]
narcolepsy and yesterday kim farm
[355]
announced the submission
[357]
of investigational new drug application
[359]
for the phase 2 trial of k of kp 1077 in
[362]
hyperinsomnia so is kim firm a good
[365]
stock to buy now
[367]
kim farm is currently trading near its
[368]
52-week low right now but analysts rate
[371]
this stock as a boy with a price target
[373]
of 11
[375]
but very interestingly about this
[377]
company the current market cap has now
[379]
dropped equal to shareholders equity
[381]
himfam have no debt and over 110 million
[384]
dollars in cash with a with a very low
[387]
cash burn
[388]
the next earnings report is due on may
[390]
12th and i expect to see more revenue
[392]
growth if you would like to see more
[394]
about this stock then comment kim
[395]
farmstock down below
[397]
180 life sciences is nasdaq listed with
[400]
the ticker atnf
[402]
180 life sciences is a clinical stage
[405]
biotechnology company focused on the
[407]
development of novel drugs to treat
[409]
inflammatory diseases fibrosis and pain
[412]
this company went public in november
[414]
2020 through a merger with a spak and
[417]
had raised over 100 million dollars
[420]
the company's primary platform is a
[421]
novel program to treat fibrosis using
[425]
anti-tnf hence the ticker at f but
[428]
they're also developing
[430]
synthetic cbd analogs
[433]
and then there is the a7 program where
[435]
180 life sciences are developing a
[437]
treatment for
[439]
ulcerative colitis and ex-smokers so
[442]
here we can see an overview of these
[444]
three programs and the technologies the
[446]
targeted diseases competitive advantages
[448]
the stage they're at and the
[450]
intellectual property involved
[452]
looking at the pipeline we can see
[454]
that these are heading into phase three
[456]
for several indications in the very near
[458]
future
[459]
and over the past week 180 have
[461]
announced final results from its phase
[463]
2b study in patients with fibrosis of
[466]
the hands the positive data results were
[468]
published in the lancet rheumatology but
[471]
is 180 life sciences a good stock to buy
[474]
right now there was only one wall street
[476]
analyst covering this stock and that is
[478]
maxim group and they have rated 180 as a
[481]
strong boy and given a prize target of
[484]
11
[485]
do you want to hear more about this
[486]
company
[487]
then drop a comment down below 180 life
[490]
sciences
[491]
guys if you've watched this far into the
[492]
video and you enjoy the content please
[494]
smash the like button and follow me on
[496]
twitter so you don't miss out on any
[498]
alerts or stock updates such as my
[500]
recent alert a red box at only 3.37
[504]
which reached as high as 10 earlier this
[506]
week next up is oxygen this company is
[510]
traded on the nasdaq with the ticker ocg
[513]
in oxygen is focused on discovering
[515]
developing and commercializing novel
[517]
gene therapies biologicals and vaccines
[520]
that improve health and offer hope for
[522]
people and global communities
[524]
one of oxygen's main focus areas is
[526]
finding
[527]
innovation
[528]
that will make hard-to-treat blindness
[530]
diseases a thing of the past
[532]
using innovation to take science in new
[534]
directions in service of patients their
[536]
breakthrough modifier gene therapy
[538]
platform has the potential to treat
[540]
multiple diseases with one drug and they
[542]
are advancing research in other
[544]
therapeutic areas to offer new options
[546]
for people with unmet medical needs
[548]
oxygen have a number of programs at
[550]
various stages in their pipeline their
[552]
leading drug is kovaxin but they also
[555]
have
[556]
ocu 400 ocu-410
[559]
and ocu-200 which are at various stages
[562]
of testing so far this year oxygen stock
[565]
has dropped over 50 percent which
[567]
represents really good buying
[569]
opportunity right now one of the reasons
[571]
for this sharp drop is that the fda
[573]
placed a clinical hold on kovacsen
[576]
but today oxygen released their latest
[579]
quarterly report where they missed
[580]
analyst estimates and so the share price
[583]
has dropped further but they also
[584]
released a business update
[586]
in this they are showing that they are
[588]
in discussions with the fda to resume
[590]
phase two and three as well as
[591]
discussions with canada held and
[593]
expansion into mexico in april
[595]
on top of this the first patient first
[598]
dosed for ocu 400 clinical trial and
[601]
growing the organization by nearly 20
[603]
further employees during the first
[605]
quarter so with the current drop is
[607]
oxygen a stock to buy or is oxygen a
[610]
good investment the overall analyst
[613]
price target consensus for oxygen is 825
[616]
with four wall street analysts giving
[618]
price targets as low as four and as high
[620]
as 15 with the consensus rating being a
[624]
moderate buy
[625]
comment oxygen down below if you want to
[627]
hear more about this company
[629]
processor pharmaceuticals is a clinical
[632]
stage biopharmaceutical company traded
[634]
on the nasdaq with the ticker pcsa this
[637]
company is focused on the development of
[639]
drug products that are intended to
[641]
provide treatment and improve quality of
[643]
life of patients who have unmet medical
[646]
needs or who have no alternative
[648]
treatments their strategy includes
[650]
identifying drugs that have potential
[652]
efficacy in patients with unmet medical
[654]
needs
[655]
identifying drug products that have been
[657]
developed or approved for other
[658]
indications but can be repurposed to
[661]
treat patients who have unmet medical
[663]
needs and identifying drugs that can
[666]
quickly be developed such that within
[668]
two to four years critical value can be
[670]
added
[671]
to meet clinical milestones while
[673]
advancing the drug closer to
[675]
commercialization processor have a
[677]
number of drugs in their pipeline that
[678]
offer multi-billion dollar opportunities
[681]
the most advanced is pcs 499 and four
[684]
other licensed drugs at various
[686]
milestone stages three of these are
[688]
cleared by the fda for clinical trials
[690]
so this is great to see
[692]
processor have many key milestones
[694]
coming up in the second half of 2022
[696]
but is processor a good stock to buy
[699]
right now looking at market beat we can
[701]
see that the general analyst rating
[703]
consensus is a buy while the analyst
[705]
price target consensus is 22
[708]
which offers an incredible 9x upside
[711]
from the current price guys if you would
[713]
like to know more about processor
[715]
and for me to do a full video on this
[717]
company then drop a comment down below
[719]
so what did you think of these biotech
[721]
stocks are you buying holding or selling
[724]
any of these
[725]
drop a comment and let me know what you
[727]
were doing and what price targets you
[728]
have and if you agree or disagree with
[731]
the wall street analysts regarding any
[733]
of these stocks i would greatly
[734]
appreciate if you could smash the like
[736]
button and hit the subscribe button if
[737]
you're new to the channel or follow me
[739]
on twitter and i'll catch you in the
[741]
next update video
Most Recent Videos:
You can go back to the homepage right here: Homepage